Biopharmaceutical company Merck (NYSE: MRK), known as MSD outside the US and Canada, on Wednesday announced positive results from two Phase 3 trials evaluating its investigational HIV treatment, doravirine/islatravir (DOR/ISL).
The once-daily, oral, two-drug regimen demonstrated non-inferiority to existing antiretroviral therapies in maintaining viral suppression at Week 48.
Data from trials MK-8591A-052 and MK-8591A-051 showed that DOR/ISL maintained HIV-1 viral suppression in adults previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or other baseline antiretroviral therapy (bART). The regimen also exhibited a safety profile comparable to the standard treatments, with no cases of treatment-emergent resistance to DOR or ISL observed.
Merck plans to submit applications for regulatory approval by mid-2025. The findings were presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Langhua Pharmaceutical passes US FDA's on-site inspection
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency